After sorting through the "report cards" of biopharmaceutical stocks that have released interim reports, we can see that most companies performed well in the first half of the year.
Wohua Pharmaceutical is the first listed company in Shandong to disclose its 2020 semi-annual report. In the first half of the year, the company achieved operating income of 484 million yuan, a year-on-year increase of 15.77%, and net profit attributable to shareholders of listed companies of 90.73 million yuan, a year-on-year increase of 190.14%.
Dongcheng Pharmaceutical stated in its interim report that the company's three major business segments of "raw materials, preparations, and nuclear medicines" in the first half of the year have basically returned to pre-epidemic levels, and operating conditions have gradually recovered, achieving operating income 1.646 billion yuan, an increase of 24.08% over the same period last year.
In the first half of the year, Shanda Huate achieved operating income of 833 million yuan, a year-on-year increase of 2.64%, and net profit attributable to shareholders of listed companies of 135 million yuan, a year-on-year increase of 51.99%.
Although the performance of Jincheng Pharmaceutical, the global leader in cephalosporin side chain intermediates, has declined year-on-year in the first half of the year, its biopharmaceuticals, specialty APIs and other pharmaceutical and chemical products still show a steady growth trend. Tianfeng Securities analyzed that although the company's preparation sector, which is closely related to hospital channel demand, was greatly affected by the epidemic in the first half of the year, its performance is expected to catch up in the second half of the year, which may not affect the upward trend of the overall performance of the year.
Regarding the future, Bo Aoke analyzed, “At present, the main source of performance of local pharmaceutical companies is the domestic market. In the future, approved products (new drugs and generic drugs) will be sold abroad and have the ability to increase the volume. It will greatly improve performance; for innovative pharmaceutical companies that are starting up, being able to obtain patented new drugs around the world will make it easier to get recognition from capital, and their valuation will be more advantageous. ”
< p> Bo Aoke introduced that gene therapy and related CDMO are currently one of the most cutting-edge technologies in biomedicine. From research and development, production to future quality control, basically every link has extremely high technical barriers. From the perspective of the field of ADC drugs, as a cutting-edge drug development technology for targeted elimination of tumors, the technical difficulties are very high. The core concern now is that toxicity is still high. If this problem can be solved, the industry is expected to develop rapidly; the field of AI pharmaceutical research is innovating the underlying drug discovery technology and greatly improving the efficiency of new drug development. In recent years, the industry has entered a period of development. , various companies have begun to cooperate with large pharmaceutical companies on technology and pipelines. It is expected that with the continuous enrichment of data volume and products under development, there will still be sufficient market space.